Nanomaterial for Cancer Diagnosis and Therapy

Dear Colleagues,

The global coronavirus disease 2019 (COVID-19) pandemic has substantially impacted our daily lives. Concomitantly, in the battle against this microorganism, we have profoundly realized the unparalleled importance of nanotechnology. The use of mRNA vaccines to prevent viral infection has demonstrated worldwide effectiveness. The development of nanotechnology in the past few decades, especially nanodelivery systems, indeed affords the possibility of this revolutionized technique to be applied in different fields. In addition to the great success in vaccination, another promising and exciting area for nanotechnology is in the diagnosis and treatment of cancers, which remains the most challenging disease that human beings confront. Although we are currently unable to completely cure cancers, especially those disseminated from the primary site to other organs, many unprecedented achievements have been made in the early diagnosis of cancers and the control of the progression of cancers, made possible by nanotechnologies. For instance, nanomaterial-based drug delivery systems help achieve the targeted delivery of chemodrugs to mitigate toxicities to normal organs. Nanomaterial-based diagnostic agents have also promoted the early and accurate detection of malignancies, which could improve the prognosis and increase the survival rate of cancers. In addition to these encouraging achievements, an increasing number of exciting applications of nanomaterials in emerging frontiers are underway, for example, the use of nanomaterials to modulate the gut microbiota for immune modulation and neurodisease prevention. In addition, the combination of nanomaterials with radiotherapy or immunotherapy is also expected to induce breakthroughs in the cancer intervention paradigm.

This Special Issue aims to present innovative, high-quality original research articles, mini review articles, and perspective articles on the synthesis, structure, physicochemical properties, and biological activity of nanomaterials with regard to cancer diagnosis and therapy.

It is our pleasure to invite you to submit a manuscript for this Special Issue. Full papers, communications, and reviews are all welcome.

Dr. Kuan Hu
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Materials is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• nanomaterials
• cancer imaging
• cancer therapy
• theranostics
• imaging-guided therapy
• drug delivery
• two-dimensional nanomaterials
• multimodal therapy
• combination therapy
• self-assembled nanomaterials